Issue release date: 12.11.2024
2Trakya University, School of Medicine, Department of Neurosurgery, Edirne, Turkey
3Ankara University, School of Medicine, Department of Neurosurgery, Ankara, Turkey
4Arel University, School of Medicine, Department of Neurosurgery, Istanbul, Turkey DOI : 10.5137/1019-5149.JTN.42622-22.2 AIM: To define whether characteristics of fluorescein staining help to distinguish low grade gliomas intraoperatively.
MATERIAL and METHODS: We studied 46 patients with supratentorial newly diagnosed noncontrast-enhancing LGGs removed by fluorescence guidance under the YELLOW 560 nm filter. Patients who were treated between July 2019 and 2022 were retrospectively analyzed. Clinical data were collected from patient records. Patients? intraoperative video recordings, pathological examination, and preoperative magnetic resonance imaging (MRI) were analyzed and compared for each patient after the operation. Histopathologically, patients were divided into WHO Grade 2 oligodendrogliomas, diffuse astrocytomas (IDH mutant, 1p19q negative tumors), and pre-glioblastomas (IDH wild type, 1p19q negative tumors). Resection margins were checked using controls contrastenhanced cranial MRI at the postoperative 24 and72 hours.
RESULTS: Our observations indicate that fluorescein primarily stains diffuse astrocytomas (IDH mutant, 1p19q negative tumors) and pre-glioblastomas (IDH wild type, 1p19q negative tumors) rather than WHO Grade 2 oligodendrogliomas.
CONCLUSION: Fluorescein staining might be an option to determine tumor borders in WHO Grade 2 glial tumors, particularly for those with a higher malignancy potential.
Keywords : Glioma, Fluorescein, Isocitrate dehydrogenase